摘要

Objectives: This study evaluates the efficacy and safety of Autologous & Tissue-specific Exosomes using Autologous Micrografting Technology (AMT) in promoting hair regrowth in Androgenetic Alopecia. Introduction: Hair loss resulting from androgenetic alopecia (AGA) benefits from advanced regenerative approaches that bridge medical and surgical modalities to optimize hair regrowth by stimulating follicular regeneration and enhancing scalp health. The autologous and tissue-specific exosomes obtained by AMT, has emerged as a promising strategy that leverages the body's intrinsic regenerative capacity. AMT technology enables the precise obtaining of patient-specific progenitor cells, exosomes, growth factors and extracellular matrix components, facilitating targeted tissue-specific paracrine communication. Materials / method: A systematic review was carried out following PRISMA guidelines, covering studies from 2019 to 2025 that evaluated the use of AMT for hair regrowth in AGA. Databases searched included PubMed, Scopus, and Embase, using keywords like “autologous micrografts,” “exosomes,” and “hair loss.” Studies involved male and female patients with early to moderate AGA. Treatments used scalp tissue processed through approved and registered medical devices to produce a biological suspension without enzymes or lab culture. Results: AMT-derived exosomes showed strong efficacy in treating AGA, with 18–29% hair density gains and up to 24% thicker shafts in 6–12 months. Anagen/telogen ratios improved, and 77.8% of men, 81.2% of women reported visible results after one session. A 12.3 hairs/cm² increase was seen in females at 3 months. AMT was safe with mild erythema resolving quicly. No serious side effects were reported, and >90% of patients were satisfied. Contraindicated in late-stage AGA and inflamed scalps. Conclusion: AMT containing tissue-specific and non manipulated exosomes represents a safe and an effective alternative for hair restoration in males (MPHL) and females (FPHL). AMT is a personalized approach using patient own regenerative potential to regulate the normal hair follicle function and improve hair density.